MedPath

Effect of darbepoetin alfa on quality of life in anemia of chronic kidney disease elderly patients with type 2 diabetes mellitus

Not Applicable
Conditions
Renal anemia with type 2 diabetes mellitus
Registration Number
JPRN-UMIN000007693
Lead Sponsor
Graduate School of Medicine, Chiba University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with cognitive impairment and on the anti cognitive impairment drug 2) Patients with impossible control of hypertension 3) Patients with impossible glycemic control 4) Patients with congestive heart failure 5) Patients with major surgery within 16 weeks 6) Patients with red blood cell (RBC) transfusions within 16 weeks 7) Patients receiving anabolic steroid hormone, testosterone enanthate, mepitiostane within 16 weeks 8) Patients with anemia caused by conditions other than renal anemia such as GI bleeding and blood desease 9) Patients with history of stroke, MI or other sever vascular complication which required a hospitalization 10) Patients with serious allergies or serious drug sensitivities 11) Patients with serious liver dysfunction (ALT or AST greater than 2 times the upper limit of hpspital standard) 12) Patients with scheduled to receive a renal replacement therapy 13) Patients having hypersensitivity to rHuEPO 14) Other patients determined to be inappropriate by physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath